BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28254377)

  • 21. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
    Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
    J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New inhibitors of fungal 17beta-hydroxysteroid dehydrogenase based on the [1,5]-benzodiazepine scaffold.
    Zivec M; Sova M; Brunskole M; Lenarsic R; Rizner TL; Gobec S
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):29-36. PubMed ID: 17373544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.
    Djigoué GB; Ngatcha BT; Roy J; Poirier D
    Molecules; 2013 Jan; 18(1):914-33. PubMed ID: 23344201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
    Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
    Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.
    Sam K; Labrie F; Poirier D
    Eur J Med Chem; 2000 Feb; 35(2):217-25. PubMed ID: 10758283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
    Maltais R; Luu-The V; Poirier D
    Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
    Ngatcha BT; Luu-The V; Poirier D
    Bioorg Med Chem Lett; 2000 Nov; 10(22):2533-6. PubMed ID: 11086723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
    Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.
    Hu GX; Zhao B; Chu Y; Li XH; Akingbemi BT; Zheng ZQ; Ge RS
    Int J Androl; 2011 Apr; 34(2):138-44. PubMed ID: 20522127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
    Vuorinen A; Engeli RT; Leugger S; Bachmann F; Akram M; Atanasov AG; Waltenberger B; Temml V; Stuppner H; Krenn L; Ateba SB; Njamen D; Davis RA; Odermatt A; Schuster D
    J Nat Prod; 2017 Apr; 80(4):965-974. PubMed ID: 28319389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17β-hydroxysteroid dehydrogenase type 1.
    Herman BE; Szabó J; Bacsa I; Wölfling J; Schneider G; Bálint M; Hetényi C; Mernyák E; Szécsi M
    J Enzyme Inhib Med Chem; 2016; 31(sup3):61-69. PubMed ID: 27424610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.